Clinical Data

brown bear in nature
Biotech

Gone are the bear days for biotech? William Blair thinks so

The analyst’s optimism is rooted in continued M&A activity, with 2025's biopharma deal volume the highest recorded in the last decade.
Gabrielle Masson Dec 12, 2025 10:55am
obesity overweight weight loss weigh

Lilly's obesity triple threat tops phase 3 efficacy forecasts

Dec 11, 2025 8:15am
Lung

GRI touts IPF safety edge, lung function gains amid cash crunch

Dec 11, 2025 5:12am
An arrow incrementally going up stairs before pointing straight up Blue background

Roche links SERD to 30% breast cancer risk reduction in phase 3

Dec 10, 2025 8:15am
Basketball players hands reaching for a ball near the hoop during a professional game

Exicure scores in phase 2 multiple myeloma program

Dec 9, 2025 10:15am
weight loss drugs obesity

Wave, Structure stocks double on obesity data readouts

Dec 8, 2025 10:50am